2-氧代吡啶-1-甲醛 | 74885-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氧代吡啶-1-甲醛
• 英文名称: 1-formyl-2(1H)-pyridone
• 英文别名: 2-Oxopyridine-1(2H)-carbaldehyde；2-oxopyridine-1-carbaldehyde
• CAS: 74885-84-0
• 化学式: C₆H₅NO₂
• 分子量: 123.111
• InChiKey: ABWLCSVFXXUOJK-UHFFFAOYSA-N

物化性质

• 熔点：
  73 °C
• 沸点：
  229.6±23.0 °C(Predicted)
• 密度：
  1.412±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氧代吡啶-1-甲醛 、 异丙醇 以 二氯甲烷 为溶剂， 反应 12.0h， 以92%的产率得到甲酸异丙酯
  参考文献：
  名称：

  Effenberger, Franz; Keil, Michael; Bessey, Eberhard, Chemische Berichte, 1980, vol. 113, # 6, p. 2110 - 2119

  摘要：

  DOI：
• 作为产物：
  描述：

  5-Amino-1-methyl-1H-imidazole-4-carboxamidine Hydrochloride 生成 2-氧代吡啶-1-甲醛
  参考文献：
  名称：

  FUJII, TOZO;SAITO, TOHRU;KIZU, KYOKO;HAYASHIBARA, HIROMI;KUMAZAWA, YUKINA+, CHEM. AND PHARM. BULL., 39,(1991) N, C. 301-308

  摘要：

  DOI：

文献信息

• Purines. XLVIII. Syntheses and proton nuclear magnetic resonance study of 2-deuterioadenines substituted or unsubstituted at the 9-position and of their N-oxygenated derivatives.
  作者：Tozo FUJII、Tohru SAITO、Kyoko KIZU、Hiromi HAYASHIBARA、Yukinari KUMAZAWA、Satoshi NAKAJIMA、Tetsunori FUJISAWA

  DOI：10.1248/cpb.39.301

  日期：——

  A detailed account is given of the syntheses of 9-alkyl-2-deuterioadenines (5b-d), adenosine-2-d (5e), and 2'-deoxyadenosine-2-d (5f) from the 9-substituted adenines 1b-f through cyclization of the aminoimidazolecarbox-amidine salts 9 or the corresponding free bases 8 with formic-d acid-d or 1-(formyl-d)-2(1H)-pyridone. Glycosidic hydrolysis of 5e with boiling 0.5N aqueous HCl afforded adenine-2-d (5a) in 77% yield. Peracid oxidation of 5a-e produced the corresponding 1-N-oxides (12a-e) in fair yields. Methylation of 9-methyl- (12b) and 9-benzyladenine-2-d 1-oxide (12d) and adenosine-2-d 1-oxide (12e) with MeI in AcNMe2 gave the corresponding 1-methoxy derivatives (13b, d, e) in good yields. Dimroth rearrangements of 13b, 13d, and 13e via the free bases 14b, 14d, and 14e furnished the N6-methoxy isomers 15b, 15d, and 15e, but their isotopic purities were unsatisfactory. Unambiguous assignments of the purine-ring proton signals in the proton nuclear magnetic resonance spectra of the unlabeled adenines (1a-f, 2a-e, 3b, d, and 10e) have been made by comparison with those of the labeled species (5a-f, 12a-e, 13b, d, and 14e).

  详细描述了通过对氨基咪唑羧氨盐9或相应游离碱8与氨基甲酸-氘或1-(甲酰氘)-2(1H)-吡啶酮的环化，从9-取代腺苷1b-f合成9-烷基-2-氘腺苷（5b-d）、腺苷-2-d（5e）和2'-脱氧腺苷-2-d（5f）。用沸腾的0.5N盐酸水解5e，得到腺苷-2-d（5a），产率为77%。对5a-e进行过氧酸氧化，得到了相应的1-N-氧化物（12a-e），产率较好。用甲基碘（MeI）在二甲基乙腈（AcNMe2）中对9-甲基（12b）、9-苄腺苷-2-d 1-氧化物（12d）和腺苷-2-d 1-氧化物（12e）进行甲基化，得到了相应的1-甲氧基衍生物（13b、d、e），产率良好。通过游离碱14b、14d和14e对13b、13d和13e进行Dimroth重排，得到了N6-甲氧基异构体15b、15d和15e，但其同位素纯度不尽如人意。通过与标记物种（5a-f、12a-e、13b、d和14e）进行比较，明确分配了未标记腺苷（1a-f、2a-e、3b、d和10e）在质子核磁共振谱中的嘌呤环质子信号。
• Substituted biaryl piperazinyl-pyridine analogues
  申请人：Rosowsky Andre

  公开号：US20060142315A1

  公开（公告）日：2006-06-29

  The present invention relates to dihydrofolate reductase inhibitors having an aromatic group and a heteroaromatic group linked by a methylene group; and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such dihydrofolate reductase inhibitors. More particularly, the present invention relates to dihydrofolate reductase inhibitors having a substituted aromatic group and a heteroaromatic group linked by a methylene group wherein at least one of the aromatic group substituents is a lipophilic residue comprising at least one acidic functional group.

  本发明涉及一种含有芳香基和杂环芳基的二氢叶酸还原酶抑制剂，它们由亚甲基连接；以及利用或包含其中一种或多种二氢叶酸还原酶抑制剂的治疗方法和制药组合物。更具体地，本发明涉及一种含有取代芳香基和杂环芳基的二氢叶酸还原酶抑制剂，它们由亚甲基连接，其中芳香基取代基中至少有一个是含有至少一个酸性功能基团的亲脂性残基。
• Methods for synthesis of diarylmethanes
  申请人：Dana-Farber Cancer Institute

  公开号：US20040267011A1

  公开（公告）日：2004-12-30

  The present invention relates to dihydrofolate reductase inhibitors having an aromatic group and a heteroaromatic group linked by a methylene group; methods of preparation of dihydrofolate reductase inhibitors that include metal mediated cross coupling of an aromatic halide or heteroaromatic halide with an organozinc reagent; and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such dihydrofolate reductase inhibitors.

  本发明涉及具有芳香基和杂环芳基的二氢叶酸还原酶抑制剂，它们由一个亚甲基连接；制备二氢叶酸还原酶抑制剂的方法包括通过金属介导的芳基卤化物或杂环芳基卤化物与有机锌试剂的交叉偶联；以及利用或包含其中一种或多种二氢叶酸还原酶抑制剂的治疗方法和制药组合物。
• PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF
  申请人：YAMANOUCHI PHARMACEUTICAL CO., LTD.

  公开号：EP0885894A1

  公开（公告）日：1998-12-23

  Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof which have the effect of inhibiting the activity of type IV phosphodiesterases and are usable as drugs, in particular, type IV phosphodiesterase inhibitors or preventives and remedies for diseases in association with the sthenic type IV phosphodiesterase activity, in particular, respiratory diseases such as bronchial asthma. In said formula (I), X represents oxygen or sulfur; R1 represents lower alkyl, cycloalkyl(lower alkyl) or cycloalkyl; R2 represents hydrogen, halogeno, lower alkyl, halo(lower alkyl), hydroxy(lower alkyl), mercapto(lower alkyl), (lower alkoxy)(lower alkyl), (lower alkylthio)(lower alkyl), (lower alkanoyloxy)(lower alkyl), (lower alkanoylthio)(lower alkyl), (lower alkanoyl)(lower alkyl), hydroxyimino(lower alkyl), (lower alkoxyimino)(lower alkyl), cycloalkyl, aryl or lower alkanoyl; R3 represents hydrogen, halogeno or lower alkyl; R4 represents hydrogen, or lower alkyl; R5 represents cycloalkyl optionally substituted by the same group as R6; naphthyl optionally substituted by the same group as R6 a 5- or 6-membered monocyclic heterocycle optionally substituted by the same group as R6, optionally fused with a benzene ring and having one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; or a group of formula (a); and R6 represents halogeno, lower alkyl, halo(lower alkyl), hydroxy, lower alkoxy, cyano or nitro.

  由通式(I)代表的化合物或其药学上可接受的盐，具有抑制IV型磷酸二酯酶活性的作用，可用作药物，特别是IV型磷酸二酯酶抑制剂或预防和治疗与sthenic IV型磷酸二酯酶活性有关的疾病，特别是呼吸系统疾病，如支气管哮喘。在所述式（I）中，X 代表氧或硫；R1 代表低级烷基、环烷基（低级烷基）或环烷基；R2 代表氢、卤素、低级烷基、卤代（低级烷基）、羟基（低级烷基）、巯基（低级烷基）、（低级烷氧基）（低级烷基）、（低级烷硫基）（低级烷基）、（低级烷酰氧基）（低级烷基）、（低级烷酰硫基）（低级烷基）、（低级烷酰基）（低级烷基）、羟基亚氨基（低级烷基）、（低级烷氧基亚氨基）（低级烷基）、环烷基、芳基或低级烷酰基；R3 代表氢、卤素或低级烷基；R4 代表氢或低级烷基；R5 代表环烷基，可任选被与 R6 相同的基团取代；萘基，可任选被与 R6 相同的基团取代；5 或 6 元单环杂环，可任选被与 R6 相同的基团取代，可任选与苯环融合，并具有一至四个杂原子，这些杂原子选自由氮、氧和硫原子组成的组；或式 (a) 的基团；以及 R6 代表卤素、低级烷基、卤代（低级烷基）、羟基、低级烷氧基、氰基或硝基。
• A New Synthetic Route to 2-Deuterioadenines Substituted or Unsabustituted at the 9-Position
  作者：Tozo Fujii、Tohru Saito、Kyoko Kizu、Hiromi Hayashibara、Yukinari Kumazawa、Satoshi Nakajima

  DOI：10.3987/r-1986-09-2449

  日期：——